Intellia Therapeutics Inc diskutieren
Intellia Therapeutics Inc
WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
23,99 €
-0,37 %
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at JPMorgan Chase & Co. from $82.00 to $79.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $66.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Barclays PLC from $148.00 to $90.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $107.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at BMO Capital Markets from $64.00 to $62.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Royal Bank of Canada from $80.00 to $70.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Raymond James from $78.00 to $57.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Morgan Stanley from $90.00 to $85.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $80.00 to $70.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target raised by analysts at BMO Capital Markets from $62.00 to $70.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for NTLA provided by MarketBeat
Neueste Beiträge
Wells_Fargo___Compan in Dycom Inds Inc. diskutieren